EA200970461A1 - ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ - Google Patents
ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫInfo
- Publication number
- EA200970461A1 EA200970461A1 EA200970461A EA200970461A EA200970461A1 EA 200970461 A1 EA200970461 A1 EA 200970461A1 EA 200970461 A EA200970461 A EA 200970461A EA 200970461 A EA200970461 A EA 200970461A EA 200970461 A1 EA200970461 A1 EA 200970461A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- pyrido
- hexahydro
- isobutyl
- izohinolin
- dimetoxi
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Рассматриваются замещенные 3-изобутил-9,10-диметокси-1,3,4,6,7,11b-гексагидро-2Н-пиридо[2,1-а]изохинолин-2-ола, которые являются ингибиторами везикулярного моноаминного переносчика 2 (VMAT2). Соединения данного изобретения имеют структуру (I)в которой Rявляется таким, как определено здесь, включая его стереоизомеры и фармацевтически приемлемые соли и сольваты. Также рассматриваются композиции, содержащие соединение данного изобретения в комбинации с фармацевтически приемлемым носителем, а также способы, относящиеся к применению в субъекте, нуждающемся в этом.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86494406P | 2006-11-08 | 2006-11-08 | |
PCT/US2007/084176 WO2008058261A1 (en) | 2006-11-08 | 2007-11-08 | Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200970461A1 true EA200970461A1 (ru) | 2009-12-30 |
EA018378B1 EA018378B1 (ru) | 2013-07-30 |
Family
ID=39110526
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200970461A EA018378B1 (ru) | 2006-11-08 | 2007-11-08 | ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ |
Country Status (16)
Country | Link |
---|---|
US (2) | US8039627B2 (ru) |
EP (1) | EP2081929B1 (ru) |
JP (1) | JP5290185B2 (ru) |
KR (1) | KR101500766B1 (ru) |
CN (1) | CN101553487B (ru) |
AU (1) | AU2007317242B2 (ru) |
BR (1) | BRPI0718247B1 (ru) |
CA (1) | CA2668689C (ru) |
DK (1) | DK2081929T3 (ru) |
EA (1) | EA018378B1 (ru) |
ES (1) | ES2402220T3 (ru) |
IL (1) | IL198250A0 (ru) |
MX (1) | MX2009004910A (ru) |
PL (1) | PL2081929T3 (ru) |
PT (1) | PT2081929E (ru) |
WO (1) | WO2008058261A1 (ru) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8039627B2 (en) | 2006-11-08 | 2011-10-18 | Neurocrine Biosciences, Inc. | Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto |
AU2009303758B8 (en) | 2008-09-18 | 2015-02-19 | Auspex Pharmaceuticals, Inc. | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
CN103003275A (zh) | 2010-06-01 | 2013-03-27 | 奥斯拜客斯制药有限公司 | Vmat2的苯并喹啉酮抑制剂 |
WO2012000308A1 (zh) * | 2010-06-29 | 2012-01-05 | 中国药科大学 | 丁苯那嗪的拆分方法 |
US8351329B2 (en) * | 2010-09-14 | 2013-01-08 | Cisco Technology, Inc. | Universal load-balancing tunnel encapsulation |
CN102285984B (zh) * | 2010-11-25 | 2012-10-10 | 江苏威凯尔医药科技有限公司 | (2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法 |
WO2012081031A1 (en) * | 2010-12-15 | 2012-06-21 | Enaltec Labs Pvt. Ltd. | Process for preparing tetrabenazine |
US9550780B2 (en) | 2012-09-18 | 2017-01-24 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
AU2013318182C1 (en) | 2012-09-18 | 2022-01-20 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
EP3770159A1 (en) * | 2013-01-31 | 2021-01-27 | Auspex Pharmaceuticals, Inc. | Benzoquinolone inhibitor of vmat2 |
EP3049087A4 (en) * | 2013-09-27 | 2017-05-24 | Auspex Pharmaceuticals, Inc. | Benzoquinolone inhibitors of vmat2 |
MX369956B (es) * | 2013-12-03 | 2019-11-27 | Auspex Pharmaceuticals Inc | Metodos para preparar compuestos de benzoquinolina. |
AU2015209330A1 (en) | 2014-01-27 | 2016-07-28 | Auspex Pharmaceuticals, Inc. | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
WO2015120110A2 (en) | 2014-02-07 | 2015-08-13 | Auspex Pharmaceuticals, Inc. | Novel pharmaceutical formulations |
AU2015213778B2 (en) * | 2014-02-07 | 2020-04-23 | Neurocrine Biosciences, Inc. | Pharmaceutical compositions comprising an antipsychotic drug and a VMAT2 inhibitor and uses thereof |
CA2939082C (en) | 2014-02-13 | 2022-06-07 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
AU2015256012B2 (en) * | 2014-05-06 | 2020-07-23 | Neurocrine Biosciences, Inc. | VMAT2 inhibitors for the treatment of hyperkinetic movement disorders |
EP3253752B1 (en) * | 2015-02-06 | 2023-08-16 | Neurocrine Biosciences, Inc. | [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto |
IL305352A (en) | 2015-03-06 | 2023-10-01 | Auspex Pharmaceuticals Inc | Methods for treating abnormal movement disorders |
TWI714567B (zh) | 2015-04-03 | 2021-01-01 | 美商英塞特公司 | 作為lsd1抑制劑之雜環化合物 |
CN113713108A (zh) * | 2015-06-23 | 2021-11-30 | 纽罗克里生物科学有限公司 | 用于治疗神经学疾病或病症的vmat2抑制剂 |
CR20180152A (es) | 2015-08-12 | 2018-08-09 | Incyte Corp | Sales de un inhibidor de lsd1 |
JP2018530612A (ja) | 2015-10-09 | 2018-10-18 | テバ、ファーマスーティカルズ、インターナショナル、ゲゼルシャフト、ミット、ベシュレンクテル、ハフツングTeva Pharmaceuticals International Gmbh | パーキンソン病の治療のための重水素化レボドパとカルビドパおよびオピカポンとの組合せ |
US10065952B2 (en) | 2015-10-30 | 2018-09-04 | Neurocrine Biosciences, Inc. | Valbenazine salts and polymorphs thereof |
JP6869988B2 (ja) | 2015-12-23 | 2021-05-12 | ニューロクライン バイオサイエンシーズ,インコーポレイテッド | (S)−(2R,3R,11bR)−3−イソブチル−9,10−ジメトキシ−2,3,4,6,7,11b−ヘキサヒドロ−1H−ピリド[2,1−a]イソキノリン−2−イル2−アミノ−3−メチルブタノエートジ(4−メチルベンゼンスルホネート)の調製のための合成方法 |
WO2017182916A1 (en) * | 2016-04-22 | 2017-10-26 | Lupin Limited | Novel process for preparation of tetrabenazine and deutetrabenazine |
EP3473623B1 (en) * | 2016-06-29 | 2020-07-15 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystal forms of nbi-98854, preparation method therefor and use thereof |
WO2018067945A1 (en) * | 2016-10-06 | 2018-04-12 | Assia Chemical Industries Ltd. | Solid state forms of valbenazine |
TW201827051A (zh) | 2016-12-02 | 2018-08-01 | 美商神經性分泌生物科學公司 | 戊苯那嗪(valbenazine)於治療精神***症或情感性精神***症之用途 |
US10703750B2 (en) | 2017-01-10 | 2020-07-07 | Sandoz Ag | Crystalline valbenazine free base |
CA3051829A1 (en) * | 2017-01-27 | 2018-08-02 | Neurocrine Bioscienes, Inc. | Methods for the administration of certain vmat2 inhibitors |
US10954235B2 (en) | 2017-02-27 | 2021-03-23 | Sandoz Ag | Crystalline forms of valbenazine salts |
WO2018164996A1 (en) | 2017-03-06 | 2018-09-13 | Neurocrine Biosciences, Inc. | Dosing regimen for valbenazine |
EP3596077A1 (en) | 2017-03-15 | 2020-01-22 | Auspex Pharmaceuticals, Inc. | Analogs of deutetrabenazine, their preparation and use |
GB201705304D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
GB201705303D0 (en) * | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
GB201705306D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
GB201705302D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
WO2018178243A2 (en) * | 2017-04-01 | 2018-10-04 | Adeptio Pharmaceuticals Limited | Pharmaceutical compositions |
JOP20190239A1 (ar) * | 2017-04-19 | 2019-10-09 | Neurocrine Biosciences Inc | مركبات مثبطة لـ vmat2 وتركيبات منها |
WO2018200605A1 (en) | 2017-04-26 | 2018-11-01 | Neurocrine Biosciences, Inc. | Use of valbenazine for treating levodopa-induced dyskinesia |
JP7250006B2 (ja) | 2017-09-21 | 2023-03-31 | ニューロクライン バイオサイエンシーズ,インコーポレイテッド | 高投与量バルベナジン製剤ならびにそれに関連する組成物、方法およびキット |
US10993941B2 (en) | 2017-10-10 | 2021-05-04 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
KR20200066661A (ko) | 2017-10-10 | 2020-06-10 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
RU2020114598A (ru) * | 2017-11-08 | 2021-12-09 | Фореси Фармасьютикалс Ко., Лтд. | Сложные эфиры дигидротетрабеназина |
US11384077B2 (en) | 2017-11-22 | 2022-07-12 | Assia Chemical Industries Ltd. | Solid state form of Valbenazine |
JP7212958B2 (ja) | 2017-12-26 | 2023-01-26 | ▲蘇▼州科睿思制▲葯▼有限公司 | バルベナジントシル酸塩の結晶形及びその製造方法並びに用途 |
CN110092785A (zh) * | 2018-01-31 | 2019-08-06 | 广东东阳光药业有限公司 | 一种丁苯那嗪的动态拆分方法 |
EP3806856A1 (en) * | 2018-06-14 | 2021-04-21 | Neurocrine Biosciences, Inc. | Vmat2 inhibitor compounds, compositions, and methods relating thereto |
BR112021000019A2 (pt) | 2018-08-15 | 2021-04-06 | Neurocrine Biosciences Inc. | Métodos para administração de certos inibidores de vmat2 |
WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
WO2020070236A1 (en) | 2018-10-04 | 2020-04-09 | Adeptio Pharmaceuticals Limited | (+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders |
CA3065236A1 (en) | 2018-12-27 | 2020-06-27 | Apotex Inc. | Novel crystalline form of valbenazine dibesylate |
WO2020213014A1 (en) | 2019-04-19 | 2020-10-22 | Mylan Laboratories Limited | An improved process for the preparation of valbenazine and its salts |
US10689380B1 (en) | 2019-07-30 | 2020-06-23 | Farmhispania S.A. | Crystalline forms of valbenazine ditosylate |
US20220340562A1 (en) * | 2019-08-12 | 2022-10-27 | Shandong Luye Pharmaceutical Co., Ltd. | Vmat2 inhibitor and preparation method therefor and application thereof |
US10940141B1 (en) | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
US20220363680A1 (en) | 2019-09-13 | 2022-11-17 | Neurocrine Biosciences, Inc. | Processes for the synthesis of valbenazine |
CN110698397A (zh) * | 2019-10-28 | 2020-01-17 | 南京红杉生物科技有限公司 | 丁苯那嗪中间体及其合成方法、应用和合成用中间产物 |
CR20230448A (es) | 2021-03-22 | 2023-10-27 | Neurocrine Biosciences Inc | Inhibidores de vmat2 y métodos de uso |
EP4330255A1 (en) | 2021-04-26 | 2024-03-06 | Neurocrine Biosciences, Inc. | Processes for the synthesis of valbenazine |
WO2023278991A1 (en) | 2021-06-30 | 2023-01-05 | Neurocrine Biosciences, Inc. | Valbenazine for use in the treatment of dyskinesia due to cerebral palsy |
KR20240027780A (ko) | 2021-06-30 | 2024-03-04 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 조현병의 부가적 치료에 사용하기 위한 발베나진 |
WO2023172849A1 (en) | 2022-03-07 | 2023-09-14 | Neurocrine Biosciences, Inc. | Valbenazine, a vmat2 inhibitor, as a free base a tosylate or ditosylate salt, for use in the treatment of chorea associated with huntington's disease |
WO2024064178A1 (en) | 2022-09-21 | 2024-03-28 | Neurocrine Biosciences, Inc. | Hexahydro-2h-pyrido[2,1-a]isoquinoline vmat2 inhibitors and methods of use |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2843591A (en) * | 1958-07-15 | Method for preparing same | ||
US3209005A (en) * | 1965-09-28 | Hexahydro-llbh-benzo[a] quinolizines and processes therefor | ||
US2852518A (en) * | 1957-05-23 | 1958-09-16 | Parke Davis & Co | Di-substituted quinoline compounds |
AU7872491A (en) | 1990-05-07 | 1991-11-27 | Vical, Inc. | Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs |
US6610841B1 (en) | 1997-12-18 | 2003-08-26 | Gilead Sciences, Inc. | Nucleotide-based prodrugs |
US7045543B2 (en) * | 2001-11-05 | 2006-05-16 | Enzrel Inc. | Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites |
GB2410947B (en) * | 2004-02-11 | 2008-09-17 | Cambridge Lab Ltd | Pharmaceutical compounds |
WO2006053067A2 (en) | 2004-11-09 | 2006-05-18 | Prestwick Pharmaceuticals, Inc. | Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders |
WO2007005283A2 (en) | 2005-06-29 | 2007-01-11 | Trustees Of Columbia University In The City Of New York | Use of dtbz for imaging endocrine pancreas and beta cell mass in type 1 diabetes |
GB0514501D0 (en) | 2005-07-14 | 2005-08-24 | Cambridge Lab Ireland Ltd | Pharmaceutical compounds |
GB0516168D0 (en) | 2005-08-05 | 2005-09-14 | Cambridge Lab Ireland Ltd | Pharmaceutical compounds |
CA2620960A1 (en) | 2005-08-06 | 2007-02-15 | Cambridge Laboratories (Ireland) Limited | 3, nb dihydrotetrabanezine for the treatment of schizophrenia and other psychoses |
US8039627B2 (en) | 2006-11-08 | 2011-10-18 | Neurocrine Biosciences, Inc. | Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto |
-
2007
- 2007-11-08 US US11/937,445 patent/US8039627B2/en active Active
- 2007-11-08 DK DK07864160.2T patent/DK2081929T3/da active
- 2007-11-08 PL PL07864160T patent/PL2081929T3/pl unknown
- 2007-11-08 BR BRPI0718247-3A patent/BRPI0718247B1/pt active IP Right Grant
- 2007-11-08 KR KR1020097011731A patent/KR101500766B1/ko active IP Right Grant
- 2007-11-08 EA EA200970461A patent/EA018378B1/ru unknown
- 2007-11-08 JP JP2009536493A patent/JP5290185B2/ja active Active
- 2007-11-08 WO PCT/US2007/084176 patent/WO2008058261A1/en active Application Filing
- 2007-11-08 CN CN2007800395790A patent/CN101553487B/zh active Active
- 2007-11-08 MX MX2009004910A patent/MX2009004910A/es active IP Right Grant
- 2007-11-08 AU AU2007317242A patent/AU2007317242B2/en active Active
- 2007-11-08 CA CA2668689A patent/CA2668689C/en active Active
- 2007-11-08 PT PT78641602T patent/PT2081929E/pt unknown
- 2007-11-08 EP EP07864160A patent/EP2081929B1/en active Active
- 2007-11-08 ES ES07864160T patent/ES2402220T3/es active Active
-
2009
- 2009-04-21 IL IL198250A patent/IL198250A0/en active IP Right Grant
-
2011
- 2011-09-20 US US13/237,709 patent/US8357697B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP2081929B1 (en) | 2013-01-09 |
EP2081929A1 (en) | 2009-07-29 |
PL2081929T3 (pl) | 2013-06-28 |
US8357697B2 (en) | 2013-01-22 |
US20120077839A1 (en) | 2012-03-29 |
KR101500766B1 (ko) | 2015-03-16 |
BRPI0718247B1 (pt) | 2021-09-21 |
JP2010509366A (ja) | 2010-03-25 |
CA2668689A1 (en) | 2008-05-15 |
KR20090079257A (ko) | 2009-07-21 |
ES2402220T3 (es) | 2013-04-29 |
CA2668689C (en) | 2015-12-29 |
US20080167337A1 (en) | 2008-07-10 |
US8039627B2 (en) | 2011-10-18 |
CN101553487A (zh) | 2009-10-07 |
ES2402220T8 (es) | 2021-12-23 |
CN101553487B (zh) | 2012-06-13 |
EA018378B1 (ru) | 2013-07-30 |
AU2007317242A1 (en) | 2008-05-15 |
PT2081929E (pt) | 2013-04-15 |
MX2009004910A (es) | 2009-07-24 |
JP5290185B2 (ja) | 2013-09-18 |
DK2081929T3 (da) | 2013-04-15 |
WO2008058261A1 (en) | 2008-05-15 |
AU2007317242B2 (en) | 2013-08-01 |
BRPI0718247A2 (pt) | 2014-01-07 |
IL198250A0 (en) | 2009-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200970461A1 (ru) | ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ | |
EA200602060A1 (ru) | Производные пирролидин-2-она и пиперидин-2-она, используемые в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы | |
EA200970207A1 (ru) | Соединения пиридо[2,3-d]пиримидинона и их применение в качестве pi3 ингибиторов | |
CY1106679T1 (el) | Αζαδικυκλικες ετεροκυκλικες ενωσεις ως τροποποιητες κανναβινοειδους υποδοχεα | |
EA201200669A1 (ru) | ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα | |
EA200800760A1 (ru) | ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα | |
EA200700185A1 (ru) | Производные хиназолиндиона в качестве ингибиторов parp | |
EA201001013A1 (ru) | Бис(сульфониламино)производные для применения в терапии | |
EA200700189A1 (ru) | Производные хиназолина в качестве ингибиторов parp | |
DE602004008098D1 (de) | Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren | |
NO20073720L (no) | Heterocyklisk substituerte fenylmetanoner som inhibitorer av glycintransportorer | |
EA200700192A1 (ru) | Производные фталазина в качестве ингибиторов parp | |
EA200201179A1 (ru) | Производные 2-аминокарбонил-9h-пурина | |
EA200970156A1 (ru) | Пиридизиноновые производные | |
EA200900924A1 (ru) | Циклизованные производные как ингибиторы eg-5 | |
SE0202463D0 (sv) | Novel compounds | |
ATE404536T1 (de) | Substituierte chinolinderivate als inhibitoren von mitotischem kinesin | |
NO20085269L (no) | 2-tioksantinderivater som fungerer som MPO-inhibitorer | |
EA200900631A1 (ru) | Замещённые пиразолы и триазолы, как ингибиторы кбв (кинезин-белок веретена) | |
WO2007017728A3 (en) | Novel heterocyclic compounds | |
EA201170722A1 (ru) | Лактамы в качестве ингибиторов бета-секретазы | |
EA200801596A1 (ru) | Новые 11-бета-гидроксиандроста-4-ен-3-оны | |
DE602004009200D1 (de) | Tetrahydrochinazolinderivate als cfr-antagonisten | |
EA200970124A1 (ru) | Производные 2-арилиндола в качестве ингибиторов npges-1 | |
EA201170595A1 (ru) | ПРОИЗВОДНОЕ ФЕНАНТРОИНДОЛИЗИДИНА И ИНГИБИТОР NFkB, СОДЕРЖАЩИЙ ЕГО В КАЧЕСТВЕ АКТИВНОГО ИНГРЕДИЕНТА |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TB4A | Correction of composition of inventors in a published eurasian patent |